Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial

Journal of Clinical Psychiatry

Volumn 67, Issue 8, 2006, Pages 1253-1260

  Álvarez Jiménez, Mario ^a,b   González Blanch, Cesar ^a   Vázquez Barquero, Jose Luis ^a,b   Pérez Iglesias, Rocío ^a   Martínez García, Obdulia ^a,b   Pérez Pardal, Teresa ^a   Ramírez Bonilla, Mari Luz ^a   Crespo Facorro, Benedicto ^a,b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; BEHAVIOR; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; EXERCISE; FEMALE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 33748961798     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0812     Document Type: Article

References (49)

1. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995;21:463-472
2. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(suppl 7):22-31
3. Baptista T. Body weight gain induced by antipsychotic drugs. Acta Psychiatr Scand 1999;100:3-16
4. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
5. Angermeyer MC, Matschisger H. Neuroleptics and quality of life: a patient survey [in German]. Psychiatr Prax 2000;27:64-68
6. Angermeyer MC, Matschisger H. Attitude of family to neuroleptics [in German]. Psychiatr Prax 1999;26:171-174
7. Kurzthaler I, Fleishhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001;62(suppl 7):32-37
8. Hägg S, Joelsson L, Mjörndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-299
9. National Institutes of Health, National Heart, Lung and Blood Institute. Clinical guides on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998;6(suppl 2):50-63
10. Wirshing DA. Adverse effects of atypical antipsychotics. J Clin Psychiatry 2001;62(suppl 21):7-10
11. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(suppl 21):25-30
12. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128
13. Addington J, Mansley C, Addington D. Weight gain in first episode psychosis. Can J Psychiatry 2003;48:272-276
14. Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999;60(suppl 21):20-24
15. Taylor D, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000;101:416-432
16. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58(suppl 10):45-49
17. Marder S, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
18. Kinon BJ, Basson MS, Gilmore JA. et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100
19. Lund BC, Perry PJ, Brooks JM, et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia and hypertension. Arch Gen Psychiatry 2001;58:1172-1176
20. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995;374:542-546
21. Simansky KJ. Serotonergic control of the organization of feeding and satiety. Behav Brain Res 1996;73:37-42
22. Mercer LP, Kelley DS, Humphries LL, et al. Manipulation of central nervous system histamine or histaminergic receptors (H1) affects food intake in rats. J Nutr 1994;124:1029-1036
23. Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701
24. Bernstein GJ. Induction of obesity by psychotropic drugs. Ann N Y Acad Sci 1987;499:203-215
25. NHS Centre for Reviews and Dissemination, University of York. The prevention and treatment of obesity. Eff Health Care 1997;3:1-12
26. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-1349
27. Menza M, Vreeland B, Minsky S, et al. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004;65:471-477
28. Vreeland B, Minsky S, Menza M, et al. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003;54:1155-1157
29. Faulkner A, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 2003;108:324-332
30. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363
31. Littrell KH, Hilligoss NM, Kirshner CD, et al. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 2003;35:237-241
32. Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatr Serv 2001;52:967-969
33. Werneke U, Taylor D, Sanders TAB, et al. Behavioural management of antipsychotic-induced weight gain: a review. Acta Psychiatr Scand 2003;108:252-259
34. Aquila R, Emanuel M. Interventions for weight gain in adults treated with novel antipsychotics. Prim Care Companion J Clin Psychiatry 2000;2:20-23
35. Aquila R. Management of weight gain in patients with schizophrenia. J Clin Psychiatry 2002;63(suppl 4):33-36
36. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press; 1997
37. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, Iowa: University of Iowa; 1983
38. Epstein LH, Squires S. The Stoplight Diet for Children: An Eight-Week Program for Parents and Children. Boston, Mass: Little Brown and Co; 1998
39. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: University of Iowa; 1983
40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
41. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-251
42. Kanders BS, Forse RA, Blackburn GL. Methods in obesity. In: Rakel RE, ed. Conn's Current Therapy. Philadelphia, Pa: WB Saunders; 1991:524-532
43. Green AI, Patel JK, Goisman RM, et al. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000;22:224-235
44. Blackburn GL. Weight gain and antipsychotic medication. J Clin Psychiatry 2000;61(suppl 8):36-42
45. Kulkarni J, Power P. Initial treatment of first-episode psychosis. In: McGorry PD, Jackson HJ, eds. The Recognition and Management of Early Psychosis. Cambridge, Mass: Cambridge University Press; 1999:184-205
46. Hummer M, Kemmler G, Kurz M, et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995;5:437-440
47. Lamberti JS, Bellnier T, Schuarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992;149:689-690
48. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
49. McGuire MT, Wing RR, Klem ML, et al. Behavioural strategies of individuals who have maintained long term weight losses. Obes Res 1999;7:334-341